Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab extension in hormone-refractory prostate cancer
NCT01824342Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2011
- Primary completion
- Feb 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of denosumab in prostate cancer (PCa), sponsored by Amgen. Started Jan 2011; status: completed.
02
Drugs
denosumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01824342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01824342.